A Phase I, Open-label, Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia and Patients With Acute Myeloid Leukemia in Complete Remission With High Risk to Relapse
Phase of Trial: Phase I
Latest Information Update: 28 May 2018
At a glance
- Drugs BI 836858 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 22 May 2018 Status changed from active, no longer recruiting to completed.
- 03 May 2018 Planned primary completion date changed from 27 Apr 2018 to 21 May 2018.
- 07 Feb 2018 Status changed from recruiting to active, no longer recruiting.